Stock CPRX CATALYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.89 USD +1.43% Intraday chart for Catalyst Pharmaceuticals, Inc. -1.59% -11.42%
Apr. 10 Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing MT
Apr. 04 Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States
DJ
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy
CI
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024
CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Catalyst Pharmaceuticals Seeks Acquisitions
CI
Top Stories at Midday: December US Nonfarm Payrolls Rise; ISM US Services Index Falls; CVS Names Finance Chief; Tesla to Recall Vehicles in China; Catalyst Prices Stock Offering
MT
Dydo Group Unit Files New Drug Application for Autoimmune Disease Treatment Candidate
MT
Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma
CI
Catalyst Pharmaceuticals Q3 Adjusted Profit, Revenue Rise; Lifts 2023 Guidance
MT
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Reports Q3 EPS $0.49
MT
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q3 Revenue $102.7M, vs. Street Est of $100.4M
MT
Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023
CI
Tranche Update on Catalyst Pharmaceuticals, Inc.'s Equity Buyback Plan announced on March 22, 2021.
CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Catalyst Pharmaceuticals Gets Two US Patent Allowances For Firdapse
MT
Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE
CI
US FDA approves Santhera's drug for rare muscular dystrophy
RE
Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
CI
Catalyst Pharmaceuticals Says Supplemental Application for Neuromuscular Disorder Treatment Accepted for Review by FDA
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CPRX Stock
  4. News Catalyst Pharmaceuticals, Inc.
  5. Highlights